Pernix Therapeutics (PTX) Reports Q2 Loss of $0.47/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Pernix Therapeutics Reports Second Quarter 2016 Financial Results and Business Update
August 11, 2016 4:01 PM EDTNet Revenue Increased 13% Sequentially Over First Quarter 2016
Recently Completed Reorganization of Management Team and Restructuring of Sales Force and Operations
MORRISTOWN, N.J., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ: PTX) (Pernix or the Company), a specialty pharmaceutical company, today announced financial results for the three and six months ended June 30, 2016.
Second Quarter 2016 Financial and Product Highlights:
Net... More